Rilematovir
Code | Size | Price |
---|
TAR-T15621-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T15621-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Rilematovir is an inhibitor of fusion protein with antiviral activity and low cytotoxicity. Rilematovir can be used in studies about respiratory syncytial virus treatment.
CAS:
1383450-81-4
Formula:
C21H20ClF3N4O3S
Molecular Weight:
500.92
Pathway:
Angiogenesis; Microbiology/Virology; JAK/STAT signaling; Tyrosine Kinase/Adaptors
Purity:
0.98
SMILES:
O=C1N(C=2C=NC=CC2N1CC(F)(F)F)CC3=CC=4C=C(Cl)C=CC4N3CCCS(=O)(=O)C
Target:
EGFR; RSV
References
1. Roymans D, et al. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun. 2017 Aug 1;8(1):167.